Core Viewpoint - Ginkgo Bioworks has submitted an application for listing on the Hong Kong Stock Exchange, with CCB International and Minmetals Capital as joint sponsors [1] Group 1: Company Overview - Ginkgo Bioworks is a leading precision medicine company in China, integrating AI capabilities deeply into the biomarker value chain [1] - The company has developed a multi-omics platform that combines foundational large models with intelligent AI agents [1] Group 2: Solutions Offered - Ginkgo Bioworks provides three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: precision diagnostics, drug development empowerment, and clinical research and translation [1]

Core Viewpoint - Ginkgo Bioworks (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming to go public on the main board [1] Company Overview - Ginkgo Bioworks is a leading precision medicine company in China, deeply integrating AI capabilities into various core aspects of the biomarker value chain [1] - The company has developed a multi-omics platform, combining foundational large models with intelligent AI, enabling a full-chain capability from the discovery and validation of multi-omics biomarkers and targets to product development and commercialization [1] Solutions Offered - The company provides three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: 1. Precision diagnostics 2. Drug development empowerment 3. Clinical research and translation [1] Innovation Framework - Ginkgo Bioworks is committed to accelerating the large-scale clinical application of AI-driven multi-omics technology through an innovative framework that synergizes multi-omics and AI [1] - The goal is to better serve the growing unmet medical needs of the vast patient population in China [1]

Core Viewpoint - GeneTech (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, indicating its position as a leading precision medicine company in China that integrates AI capabilities into the biomarker value chain [1] Company Overview - GeneTech utilizes a self-developed multi-omics platform, combining foundational large models and intelligent AI to create a comprehensive capability from the discovery and validation of multi-omics biomarkers and targets to product development and commercialization [1] Solutions Offered - The company provides three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: 1. Precision Diagnosis 2. Drug Development Empowerment 3. Clinical Research and Translation [1]

Group 1 - The core viewpoint of the article is that Geneplus Technology (Shaoxing) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, indicating its intention to go public [1] - Geneplus is recognized as a leading precision medicine company in China, integrating AI capabilities deeply into the biomarker value chain [1] - The company has developed a comprehensive capability from biomarker and target discovery, validation, product development to commercialization based on its self-developed multi-omics platform [1] Group 2 - Geneplus offers three main solutions targeting hospitals, pharmaceutical and biotechnology companies, and medical research institutions: precision diagnosis, drug development empowerment, and clinical research and translation [1] - The company is backed by joint sponsors, including CCB International and Minmetals Capital, for its listing process [1] - The shares are priced at RMB 1.00 per H share, with additional fees for commissions and transaction costs outlined in the prospectus [1]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Geneplus Technology (Shaoxing) Co., Limited* 吉因加科技（紹興）股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資料予香港公眾人士。 本 申 請 版 本 為 草 擬 本，其 內 所 載 資 料 並 不 完 整，亦 可 能 會 作 出 重 大 變 動。 閣 下 閱 覽 本 文 件，即 代 表 閣下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處長註冊 的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士提供。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Geneplus Technology (Shaoxing) Co., Limited* 吉因加科技（紹興）股份有限公司 (the "Company") (A joint stock company established in ...

Group 1 - The core viewpoint of the article highlights that the precision medicine sector experienced a 1.16% increase on December 17, with Di'an Diagnostics leading the gains [1] - The Shanghai Composite Index closed at 3870.28, up by 1.19%, while the Shenzhen Component Index closed at 13224.51, up by 2.4% [1] - The article provides a summary of the fund flow in the precision medicine sector, indicating a net outflow of 101 million yuan from main funds and 164 million yuan from speculative funds, while retail investors contributed a net inflow of 265 million yuan [1] Group 2 - The article includes a table detailing the individual stock performance within the precision medicine sector, although specific stock data is not provided in the text [1] - The information is compiled from public sources and generated by AI algorithms, indicating a reliance on data analysis for insights [1]

Core Insights - The precision medicine sector experienced a slight increase of 0.53% on December 12, with BGI Genomics leading the gains [1] - The Shanghai Composite Index closed at 3889.35, up 0.41%, while the Shenzhen Component Index closed at 13258.33, up 0.84% [1] Stock Performance - BGI Genomics (688114) saw a closing price of 64.50, with a significant increase of 7.68% and a trading volume of 86,400 shares, resulting in a transaction value of 540 million yuan [1] - Other notable performers included: - BGI (300676) with a closing price of 45.71, up 3.86% [1] - Wondfo Biotech (300685) at 21.55, up 1.41% [1] - Berry Genomics (000710) at 11.18, up 0.72% [1] - WuXi AppTec (603259) at 94.05, up 0.70% [1] Capital Flow - The precision medicine sector saw a net outflow of 1.022 billion yuan from institutional investors, while retail investors contributed a net inflow of 586 million yuan [2] - The capital flow for specific stocks included: - BGI Genomics (688114) had a net inflow of 22.93 million yuan from institutional investors [3] - Anke Bio (300009) experienced a net inflow of 3.38 million yuan from institutional investors [3] - However, ST Xiangxue (300147) faced a net outflow of 2.93 million yuan from institutional investors [3]

Core Viewpoint - The strategic collaboration between Mirxes and Jingtai Technology aims to integrate their strengths in early cancer detection and drug development, creating a comprehensive "diagnosis and treatment integration" solution for high-incidence cancers in Asia [1] Collaboration Model - The partnership focuses on building a closed-loop ecosystem of "detection + research" [2] - Mirxes will act as a "frontline detection and risk assessment expert" utilizing its leading position in blood-based miRNA cancer screening [3] - Jingtai Technology will serve as an "intelligent drug discovery engine" leveraging quantum physics, AI, and robotic experimentation [3] - Both companies plan to create a disease database focused on the Asian population to drive the discovery of new diagnostic markers and therapeutic targets [3] Strategic Intent - This collaboration signifies Mirxes' strategic shift from solely "early diagnosis" to a broader "diagnosis and treatment integration" approach [4] - By closely aligning with upstream drug development platforms, the company aims to participate in higher-value treatment segments, enhancing its competitive barriers and customer loyalty [5] Fundamental Support - Mirxes' strategic advancement is backed by improving fundamentals [6] - Recent business expansions include inclusion in the Hang Seng Composite Index, endorsement from Malaysia's sovereign fund, and obtaining key market access qualifications [7] - The company reported a revenue of $10.5 million in the first half of the year, with core early screening business revenue growing by 50% year-over-year [7] - Gross margin improved significantly from 49% to 67.6%, indicating strong product capability and cost control [7] - Cash reserves reached $108 million, providing financial flexibility for R&D collaboration and market expansion [7] Investment Perspective - Mirxes currently exhibits strong growth in core business and a clear long-term strategy [8] - Short-term certainty is based on the commercial progress of its gastric cancer screening and the effectiveness of its high-margin business model [9] - Long-term potential is enhanced by collaborations with major players like Watson and Jingtai, which open avenues for extending from diagnostic data to treatment [9] Conclusion - The strategic partnership between Mirxes and Jingtai Technology represents a forward-looking move to break through the limitations of the early screening industry and tap into the larger precision medicine market [11] - The company is at a critical juncture of "performance realization" and "model transition," necessitating attention to both existing business growth and the potential value creation from the new ecosystem [12]

Group 1 - Geneplus has completed a 300 million yuan Series D financing round, with investments from Shaoxing City Yuecheng District Science and Technology Innovation Fund and Beijing Changping Industrial Development Investment Fund among others [2][3] - The financing will primarily be used for the research and development of AI multi-omics technology, expansion of biomarker innovation pipelines, and deepening of global service networks, enhancing the company's capabilities in precision diagnostics and new drug development [3] - Geneplus, established in April 2015, focuses on precision medicine and has created an AI-driven multi-omics platform, achieving significant breakthroughs in tumor MRD monitoring and integrated NGS precision diagnostic platforms [3] Group 2 - The company aims to convert AI multi-omics innovative technologies into accessible and reliable clinical solutions, with plans to increase investment in AI multi-omics R&D and accelerate the commercialization of core products like MRD monitoring and early tumor screening [3] - Following the Series D financing, Geneplus will continue to deepen its "AI + multi-omics + full-chain" development strategy, solidifying its leading position in precision diagnostics while enhancing its full-process service capabilities for new drug development [3] - The company is committed to exploring innovative applications of AI in precision medicine to improve domestic diagnostic levels and contribute to public health [3]